315 ImmunoPET and Biodistribution with Human Epidermal Growth Factor Receptor 3 Targeting Radiolabeled Antibody 89Zr-GE-huMAb-HER3

@article{Scheltinga2012315IA,
  title={315 ImmunoPET and Biodistribution with Human Epidermal Growth Factor Receptor 3 Targeting Radiolabeled Antibody 89Zr-GE-huMAb-HER3},
  author={Anton G. T. Terwisscha van Scheltinga and Marjolijn N. Lub-de Hooge and K. R. Abiraj and Carolien P. Schröder and Linda Pot and Birgit Bossenmaier and Marlene Pickl and Thomas Friess and Jos G. W. Kosterink and Ege de Vries},
  journal={European Journal of Cancer},
  year={2012},
  volume={48},
  pages={96-97}
}
View via Publisher
4 Citations

4 Citations

Citation Type

Citation Type

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab)
TLDR
A positron emission tomography (PET) companion diagnostic to MEHD7945A is reported and evaluated in pancreatic cancer and specificity of the probe for EGFR and/or HER3 was further examined.
University of Groningen Antibody imaging as biomarker in early cancer drug development and treatment
TLDR
The technology has great potential to inform decisions in early clinical development by addressing fundamental questions of drug delivery, dose finding, and target modulation, thereby prioritizing the right agents.
Antibody positron emission tomography imaging in anticancer drug development.
TLDR
This approach could potentially increase the power and value of early trials by improving patient selection, optimizing dose and schedule, and rationalizing observed drug responses.
HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.